A non-invasive cardiac mapping system transforming arrhythmia diagnosis and treatment through real-time 3D insights
The challenge
In 2023, circulatory diseases were the leading cause of death in the EU, accounting for 1.7 million deaths (32.7% of total)1 Among these, cardiac arrhythmias—affecting an estimated 240 to 400 million people globally—represent a significant health burden due to their potential to cause stroke and sudden death2, 3.
The most common sustained cardiac arrhythmia is atrial fibrillation (AF), characterized by an irregular and often rapid heart rhythm. As of 2019, AF affected approximately 59.7 million people worldwide, with numbers expected to rise due to aging populations and improved detection. In the EU alone, over 11 million people live with AF, and this number is projected to double by 20604.
AF poses serious risks to patients, significantly increasing the likelihood of stroke, heart failure, and premature death. It also causes debilitating symptoms such as palpitations, fatigue, and shortness of breath, which severely impact quality of life and mental health. Unfortunately, treatments often fall short—up to 50% of patients experience recurrence after the first ablation, particularly in persistent AF cases, requiring multiple procedures and increasing emotional and physical burden. The financial impact is substantial, both in terms of out-of-pocket expenses and indirect costs like lost income due to hospitalizations and ongoing symptoms. In Europe, AF-related healthcare costs represent 1–3% of total national health expenditures, with estimated annual costs reaching €13.5 billion5, 6.
Healthcare professionals face their own challenges: the lack of precise, non-invasive cardiac mapping tools makes it difficult to accurately localize arrhythmogenic sites. Current invasive techniques are time-consuming and limited in scope, complicating treatment planning. This contributes to clinician frustration, rising workloads, and burnout as AF prevalence continues to grow.
For healthcare systems and policymakers, AF represents a growing public health concern. With an aging population and rising prevalence, the burden on national budgets is significant—Germany alone spends over €3 billion annually on AF-related care. While there’s strong pressure to adopt innovative medical technologies that improve patient outcomes and reduce costs, updating reimbursement frameworks remains a complex and slow-moving process.
Recognizing these unmet needs, the Strategic Research Agenda for Cardiovascular Disease (SRA-CVD) by the European Research Area Network on Cardiovascular Diseases (ERA-CVD) has identified improvement in arrhythmia treatment as a priority. Central to this is the ability to accurately localize the arrhythmogenic site within the myocardium. The success of ablation interventions, a key treatment strategy, depends on precisely identifying the pathological region of the heart muscle.
However, a major limitation in current mapping systems is their inability to provide full-volume visualization of cardiac electrical activity with high temporal and spatial resolution. Endocardial mapping can only assess the inner heart surface and fails to detect arrhythmias originating from the epicardium or mid-myocardium. These blind spots contribute significantly to the high failure rates of cardiac ablations and highlight the urgent need for technological innovation in cardiac mapping.
The solution
Corify Care’s ACORYS technology is a cutting-edge, non-invasive cardiac mapping system developed to precisely identify arrhythmogenic sites in patients with atrial fibrillation (AF) and other complex arrhythmias.
As a Digital Medical Device, ACORYS integrates advanced software algorithms with specialized hardware to produce real-time, three-dimensional maps of the heart’s electrical activity—providing insights far beyond those offered by traditional invasive techniques. It supports a range of medical applications, including diagnosis, monitoring, and treatment guidance for cardiac arrhythmias.
ACORYS stands out for its speed and accuracy: it can generate cardiac maps up to 10 times faster than conventional methods, reducing mapping time from 30 minutes to just 3. This efficiency enables rapid, data-driven clinical decisions and has demonstrated a significant improvement in ablation success rates—from 48% to 89% 7.
Corify’s innovation journey has been strongly supported by EIT Health. In 2019, the AF-FINE project helped refine both the ACORYS technology and Corify’s business model, culminating in the 2020 Award for Europe’s Most Innovative Product from the EIT. Continued support came through the Amplifier SAVE-COR project, which was instrumental in obtaining the CE Mark for ACORYS.
ACORYS has since undergone extensive clinical validation, having been used in more than 1,400 patients across several hospitals in Spain, with pilot programs also conducted in Portugal and Sweden.
Expected impact
Health Impacts will be tracked through clinical studies, measuring a 48% to 86% increase in arrhythmia treatment efficacy. ACORYS will also enable real-time global mapping, accelerating the process from 30 minutes with standard catheter mapping to just 3 minutes. Expected results include reductions in both 23 complications and re-interventions, as well as optimized therapeutic planning, all aimed at advancing cardiovascular research and improving patient outcomes.
Economic Impacts include reductions in procedure times and inpatient stays, allowing more efficient use of medical staff and optimized operating room scheduling, thus lowering costs associated with resource use in specialized care areas.
Environmental Impacts include reduced wear on invasive, high-tech equipment, and a decrease in consumables, such as catheters, which will be measured by comparing usage levels before and after ACORYS’s implementation.
Expected social outcomes include improved clinical outcomes with reduced long-term disability and dependence, faster outpatient procedures that lower travel and lodging costs, quicker patient return to work, and a reduced burden on caregivers.
External Partners
- Corify Care SL (Activity Leader)
- Charité – Universitätsmedizin Berlin
- University Hospital Frankfurt / Goethe University Frankfurt
References
[1] Eurostat 2023 https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Cardiovascular_diseases_statistics
[2] Li, et al. (2022). “Global, regional, and national burden of disease study of atrial fibrillation/flutter, 1990–2019: results from a global burden of disease study, 2019.“ BMC Public Health, https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-022-14403-2
[3] Van Gelder, et al. (2024). “2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO)“, European Heart Journal, https://doi.org/10.1093/eurheartj/ehae176
[4] Hidrincks et al., (2021). “ 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC“, European Heart Journal, 10.1093/eurheartj/ehaa612
[5] Camm et al., (2012). “2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association”, European Heart Journal, 10.1093/eurheartj/ehs253
[6] Fuster et al., (2006). “2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines”, European Heart Journal, 10.1093/eurheartj/ehl176
[7] Invers et al., (2024). “ Regional conduction velocities determined by noninvasive mapping are associated with arrhythmia-free survival after atrial fibrillation ablation“, Heart Rhythm, 10.1016/j.hrthm.2024.04.063
Members
CLC/InnoStars: Spain
Partner classification: Municipality / City, Tech Transfer, Clusters, Other NGOs
The Agency for Health Quality and Assessment of Catalonia is a public legal entity subject to private law, under the auspices of the Generalitat of Catalonia’s Health Services Department which serves public policy. The mission of AQuAS is to promote knowledge and know -how aimed at improving the quality, safety and sustainability of the Catalonian healthcare system.
Agency for Health Quality and Assessment of Catalonia
Agency for Health Quality and Assessment of Catalonia, Carrer de Roc Boronat, 81, 08005 Barcelona, Spain
Key Activities in Social Innovation
Healthcare provision, Payers
Key Activities in Education
Healthcare professional education/training
CLC/InnoStars: Spain
Partner classification: Research
Partner type: Linked/Affiliated Party
The Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) is a public research centre dedicated to biomedical research, founded in 1996 to broaden the clinical research of the Hospital Clinic de Barcelona (HCB). With >1,500 original articles and >2,500 publications annually, IDIBAPS is one of the leading biomedical research centres in Spain driving forward original multidisciplinary biomedical research on multiple diseases affecting our society, with the mission to translate “knowledge into cure”. The broad vision of IDIBAPS Strategic Plan is to improve the health and quality of life of citizens through high impact research and collaborations, at the highest level of scientific integrity, public accountability, and social responsibility. The close interaction of 100 clinical and laboratory research groups, composed by more than 460 Principal Investigators, drives forward original translational and multidisciplinary research oriented to solve relevant biological and clinical questions for human health. The researchers have access to novel and first-class infrastructures available together with six own core facilities offering a wide range of services under strict quality management controls performed at all levels. The institution has also a strong track record working in European projects (e.g. 90 projects obtained along H2020 and 36 in Horizon Europe) and has a dedicated European Projects Office (OPE) and the Knowledge and Technology Transfer Office (KTT).
Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Carrer del Rosselló, 149, 08036 Barcelona, Spain
Key Activities in Research and Developement
1600 researchers in 100 research groups
Key Activities in Corporate Innovation
Key Innovation capacities
-Strong expertise in EIT Health projects (involved in +30 projects from all pillars since 2016)
-Internationally recognized KOLs in different fields (+100 management positions in international scientific and clinical societies)
-High volume of Clinical Trials (+200 new clinical trials performed every year) with a dedicated Clinical Trial Unit, offering an integral support
-Technology transfer (12 active spin-off; +70 active patent families)
Key Activities in Business Creation
Testing & Validation
Key Activities in Education
Medical faculties, Healthcare professional education/training
CLC/InnoStars: Spain
Partner classification: Business
GENESIS Biomed is a consultancy firm in the biomedical healthcare sector specialized in providing consulting services to spin-off and start-up companies, entrepreneurs and research centers. Based in our expertise we help entrepreneurs and researchers to shape their business plan and we support them in the private fundraising process. We have worked on 253 projects of 15 different types and we have raised more than 67.5 M€ in the last 6 years. Our expertise domains are biopharmaceutical, biotechnological, medical devices, in vitro diagnostic, digital health nutraceutical and cosmetic. With more than 20 years of expertise in the healthcare sector, we are born in May 2017 and we are located in the Barcelona Science Park and in the center of Madrid.
GENESIS Biomed
GENESIS Biomed, Carrer de Baldiri Reixac, 4-12-15, 08028 Barcelona, España
CLC/InnoStars: Spain
Partner classification: Research, Hospital / University Hospital
Hospital Clinic of Barcelona (HCB), founded in 1906, is a university hospital with 4,500 professionals covering most of medical and surgical specialties. It belongs to the Catalan Public Hospital Network and it is both a high-complexity tertiary hospital and a community hospital providing services to more than half million citizens. HCB is placed in Spain in a top position in the areas of research and innovation (e.g. top participant in Societal Challenge 1-Health in H2020).
Hospital Clínic de Barcelona
Carrer de Villarroel, 170, 08036 Barcelona, Spain
Key Activities in Corporate Innovation
Key Innovation capacities
-Strong expertise in EIT Health projects (involved in +30 projects from all pillars since 2016)
-Internationally recognized KOLs in different fields (+100 management positions in international scientific and clinical societies)
-High volume of Clinical Trials (+200 new clinical trials performed every year) with a dedicated Clinical Trial Unit, offering an integral support
-Technology transfer (12 active spin-off; +70 active patent families)
Key Activities in Social Innovation
Healthcare provision
Key Activities in Business Creation
Testing & Validation
Key Activities in Education
-Professionals (AulaClinic) (+500 actions and +7500 participants in 2021) http://www.aulaclinic.com/
-Patients (Patient Experience Forum - Living Lab) (20 focal groups and 75 participants in 2021) https://www.clinicbarcelona.org/uploads/media/default/0002/77/9d52d7598494a2a45a34f19a56a6c4af1af6a0ae.pdf
-Citizens (PortalCLÍNIC) (+5 million visits in 2021) https://www.clinicbarcelona.org/en/portalclinic
CLC/InnoStars: Germany
Partner classification: Tech Transfer, Clusters, Other NGOs
The Medical Valley European Metropolitan Region Nuremberg is an internationally leading cluster in the medical engineering sector. The\narea is home to highly specialized research facilities, global players and many upcoming companies.
Medical Valley European Metropolitan Region Nuremberg
Medical Valley European Metropolitan Region Nuremberg, Henkestraße 91, 91052 Erlangen, Germany
Key Activities in Business Creation
Incubation, Technology Transfer, Business coaching
CLC/InnoStars: Spain
Partner classification: Municipality / City, Hospital / University Hospital
Servicio Madrileño de Salud (SERMAS) is the public health provider of the region of Madrid. SERMAS belongs to the Spanish National Health System and provides services to more than 6 million citizens through 38 hospitals and 424 primary care centres. SERMAS is an international reference for high-specialized medicine; it is equipped with state-of-the art stage technologies and characterized by high-qualified health professionals distributed in three domains: primary care, hospital care and emergency care through SUMMA 112. SERMAS has one of the best public primary care systems in good coordination with hospital care and social services in order to provide integrated care and achieve real impact on patients and families. In order to improve health research management and coordination, SERMAS works with 13 Research Foundations that support from the economic and administrative point of view research and innovation that originates at university hospitals, primary care, the emergency medical service and public health covering all areas of specialties and including communication and information technologic departments. These public research foundations focus on innovation and translational research, seeking for real outcomes in healthcare. SERMAS is committed to ensure the continuous improvement of quality.
Key Activities in Social Innovation
Healthcare provision, Payers
Key Activities in Business Creation
Technology Transfer, Testing & Validation
Key Activities in Education
Medical faculties, Healthcare professional education/training
CLC/InnoStars: InnoStars
Partner classification: Education, Research
NOVA University Lisbon has a strong commitment to health sciences that encompasses all its nine organic units - ranging from molecular biology to the health of populations. Three of NOVA’s schools are directly committed to health: NOVA Medical School, the Institute of Hygiene and Tropical Medicine and the National School of Public Health, while two others are dedicated to molecular biology and life materials as well as biomedical engineering, by so contributing to life sciences: the school of biotechnology and engineering (Faculty of Science and Technology) and the school of molecular biology (Institute of Chemical and Biological Technology António Xavier). Faculty of Social and Human Sciences, the school of management (Nova School of Business and Economics), the school of data (NOVA Information Management School) and the Law School, do collaborate to research in health sciences, namely covering social dimensions and interactions of health. We may rightly state that NOVA covers the entire health spectrum - from molecule to patient's bedside - linking fundamental biology, technology and health care to ultimately improve the health of populations. NOVAhealth platform mission is to create health value through scientific production, the dissemination of knowledge and the implementation of innovative solutions, useful for the health of populations. To fulfil this mission, we promote research collaborations between NOVA's academic units, as well as establish partnerships with industry and society, focused on research missions, with the identified purpose of responding to concrete problems. NOVAhealth is organized into ten research groups, where members of all NOVA organic units collaborate as well as other external members: Ageing, Nutrition, Value Improvement for Health and Care, Climate Change Impact on Public Health, Integrated Care, Migration and Health, Quality Improvement and Patient Safety, Health Systems and Policies and Tropical Health.
Universidade Nova de Lisboa
CLC/InnoStars: Spain
The Universitat Politècnica de València (UPV) positions itself as an ideal strategic partner for EIT Health thanks to its strong track record in applied research and its leadership in technological innovation in Spain and Europe. Its ability to develop disruptive solutions in key health areas, such as biotechnology, applied artificial intelligence, medical devices, biomaterials, and biosensors, reflects its commitment to scientific progress.
Furthermore, its active participation in European programs such as H2020 and Horizon Europe demonstrates its expertise in international collaboration and its ability to integrate into multidisciplinary consortia. The UPV has a dynamic entrepreneurial ecosystem, driven by the Spin-UPV program, which fosters the incubation and acceleration of health-related startups.
Its close connection with the healthcare sector is materialized through established collaborations with leading hospitals and research institutes, such as IIS La Fe, FISABIO, INCLIVA, and FiHGUV, through programs aimed at generating seed projects and promoting innovation.
Additionally, the UPV boasts high-level infrastructure, represented by its knowledge transfer office, UPV-Innovación, and its science park, the Ciudad Politécnica de la Innovación, which strengthen knowledge transfer and the creation of socioeconomic impact.
Overall, the UPV not only provides academic and technological excellence but also a proven capacity for innovation, collaboration, and impact generation in the health sector in Europe.
Universitat Politècnica de València (UPV)
Universitat Politècnica de València (Technical university of Valencia) (UPV), Camino de Vera, s/n, 46022, Valencia (Spain)
Key Activities in Research and Developement
- Research in biomedical engineering and medical devices
- Development of AI and machine learning applications for healthcare
- Biomechanics and ergonomics research
- Research in telemedicine and e-health solutions
- Development of rehabilitation technologies
- Research in biomedical imaging and signal processing
Key Activities in Corporate Innovation
- Collaboration with healthcare industry partners for technology transfer
- Innovation partnerships with hospitals and healthcare providers
- Joint development projects with medical device companies
- Participation in healthcare innovation clusters
- Development of patented healthcare technologies
Key Activities in Social Innovation
- Projects focused on aging population solutions
- Development of assistive technologies for disabled people
- Health promotion and prevention initiatives
- Community health programs
- Solutions for healthcare accessibility
Key Activities in Business Creation
- Support for healthcare startups through IDEAS UPV
- Incubation services for health-tech companies
- Mentoring programs for healthcare entrepreneurs
- Access to specialized laboratories and equipment
- Connection with healthcare industry networks
Key Activities in Education
- Biomedical Engineering degree programs
- Health technology management courses
- Medical device design and development training
- Healthcare innovation and entrepreneurship programs
- Continuing education in healthcare technologies
CLC/InnoStars: Germany
Partner classification: External Project Partners
Charité is one of the largest university hospitals in Europe. Here, doctors and scientists research, heal and teach at the highest international level.